Investor relations

We are steadfast in our efforts to develop novel medicines that redefine treatment paradigms for autoimmune and inflammatory conditions.

Investors

Nektar is a clinical-stage biotechnology company developing novel therapies to treat immune-mediated diseases in fundamentally unique ways.

We create differentiated therapeutic candidates that target key mechanisms central to disease pathophysiology with the goal of resolving immune system imbalances. Nektar pursues paradigm-shifting opportunities where patient need and scientific potential converge, turning innovative science into transformational therapies.

Corporate presentation

View all

Nektar Investor and Media Contacts

Investor Relations

Vivian Wu (415) 450-8976

Media

Jonathan Pappas (857) 205-4403

Transfer Agent and Stockholder Services

Computershare Shareholder Services

P.O. Box 43006
Providence, RI 02940-3006

(877) 290-2261 (201) 680-6578

Investor relations

Nektar is a clinical-stage biotechnology company developing novel therapies to treat immune-mediated diseases in fundamentally unique ways.

News

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

Events

Nektar Therapeutics Q4 2025 Financial Results

TD Cowen 46th Annual Health Care Conference

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis

Nektar Investor and Media Contacts

Transfer Agent and Stockholder Services